Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 2, 2004, Pages 84-88

  Sim, Justein S N ^a   Farquharson, Colin ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Angiotensin II; Endothelium; Losartan; Nitric oxide; Renin angiotensin system

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; LOSARTAN; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; SODIUM CHLORIDE; VASODILATOR AGENT;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN BLOOD LEVEL; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL TONE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FUNCTION TEST; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VASOCONSTRICTION; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 3543020924     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.015     Document Type: Article

References (50)

1. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
2. Van Gilst WH, Kingma H, Peels KH, Dambrink JH, St John Sutton M. Which patient benefits from early ACE inhibition after myocardial infarction? Results of a 1 year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS). J Am Coll Cardiol 1996;8:114-21.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. N Engl J Med 2000;342:145-53.
5. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb DJ. Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators. Hypertension 1995;25:918-23.
6. Nakamura M, Funakoski T, Yoshida H, Arakawa H, Suzuki T, Hiramori K. Endothelium dependent vasodilatation is augmented by angiotensin-converting enzyme inhibitors in healthy volunteers. J Cardiovasc Pharmacol 1992;20:949-54.
7. Butler R, Morris AD, Struthers AD. Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci (Lond) 2002;101(1):53-8.
8. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678-84.
9. Hirooka Y, Imaizumi H, Masaki S et al. Captopril improves impaired endothelium dependent vasodilatation in hypertensive patients. Hypertension 1992;20:175-80.
10. Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. (TREND) Circulation 1996;94:258-65.
11. Drexler H, Kurz M, Jeserich T, Munzel T, Harnig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with heart failure. Am J Cardiol 1995; 76:13E-18E.
12. Griendling KK, Minieri CA, Ollerenshaw JA, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.
13. Berkenboom G. Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors. Am J Cardiol 1998; 82:11S-13S.
14. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;76:3E-12E.
15. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36:1461-6.
16. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000;35:501-06.
17. Prasad A, Narayanan S, Mincemoyer R, Tupas-Habib T, Ellahham S, Quyyumi AA. Acute and long term effects of angiotensin type 1 receptor inhibition on endothelial dysfunction in atherosclerosis. Circulation 1998;98:I-607.
18. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary heart disease. Circulation 2001;103:799-805.
19. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide: an endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 1996;93:1155-9.
20. Moncada S, Radomski MW, Palmer RM. Endothelium derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988;37:2495-501.
21. Feelisch M, Noack E. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30.
22. Greenfield ADM, Paterson GC. Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (Lond) 1954;125:508-24.
23. Whitney RJ. The measurement of volume changes in human limbs. J Physiol (Lond) 1953;121:1-27.
24. Kurland L, Melhus H, Sarabi M, Millgard J, Ljunghall S, Lind L. Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects. Clin Physiol 2001;21:343-9.
25. Butler R, Morris A, Burchall B, Struthers AD. The DD ACE genotype polymorphism is associated with endothelial dysfunction in normal man. Hypertension 1999;33:1169-74.
26. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6.
27. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long term follow up of patients with mild coronary disease and endothelial dysfunction. Circulation 2000;101:948-54.
28. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101: 1899-906.
29. Egashira K, Hirooka Y, Kai H et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation 1994;89: 2519-24.
30. Farquharson C, Struthers AD. Spironolactone increases NO bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular AI/AII conversion in patients with CHF. Circulation 2000;101:594-7.
31. Gilligan DM, Sack MN, Guetta V et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolaemia. J Am Coll Cardiol 1994;24:1611-17.
32. Vusuiku F. Effects of vitamin E on the endothelium: equivocal? α-tocopheral and endothelial dysfunction. Cardiovasc Res 2001;51:198-201.
33. Muhlen BV, Millgard J, Lind L. Effects of digoxin, furosemide, enalaprilat and metoprolol on endothelial function in young normotensive subjects. Clin Exp Pharmacol Physiol 2001;28:381-5.
34. Millgard J, Lind L. Divergent effects of different antihypertensive drugs on endothelium-dependent vasodilation in the human forearm. J Cardiovasc Pharmacol 1998;32:406-12.
35. Antony I, Lerebours G, Nitenburg A. Angiotensin converting enzyme inhibition restores flow dependent and cold pressor test induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22.
36. Dahlof B, Devereux RB, Kjeldsen SE et al. The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: 995-1003.
37. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
38. Beckman JS, Beckman TW, Chen J Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
39. Leeuwenburgh C, Hardy MM, Hazen SL et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997; 272:1433-6.
40. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997;100:2153-7.
41. Dijkhorst-Oei LT, Stroes ES, Koomans HA, Rabelink TJ. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 1999;33:420-4.
42. Heitzer T, Just H, Munzel T.Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94(1):6-9.
43. Ting HH,Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97(1):22-8.
44. Ting HH,Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolaemia. Circulation 1997;95:2617-22.
45. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti Al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9.
46. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363-8.
47. Gokce N, Keaney JF Jr, Frei B et al. Long-term ascorbic acid administration reverses endothelial dysfunction in patients with coronary artery disease. Circulation 1999;99:3234-40.
48. Searles CD, Harrison DG. The interaction of nitric oxide, bradykinin and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999;104:1013-14.
49. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 ocerexpression activates the vascular kinin system and causes vasodilatation. J Clin Invest 1999;104:925-35.
50. Warnholtz A, Nickenig G, Schulz E et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for the involvement of the renin-angiotensin system. Circulation 1999;99:2027-33.